Pfizer seeks approval for new Viagra use

Share this article:
Pfizer has filed applications with the FDA and European regulators for approval of its male impotence drug Viagra to treat the potentially fatal lung disorder pulmonary arterial hypertension.
The drug would be called Revatio for the new indication, not Viagra, and would be manufactured and marketed in a different dosage, color and shape than Viagra, the New York-based drug maker said.
Pulmonary arterial hypertension treatments include calcium channel blocker drugs Norvasc and Procardia XL, also manufactured by Pfizer and Biovail's Cardizem.
An approval would add to worldwide sales of Viagra, which generated $1.9 billion in revenue for 2003, according to a Bloomberg News report.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.